Immutep Ltd (AU:IMM) has released an update.
Immutep Ltd has reported encouraging preliminary results from its Phase IIb TACTI-003 trial, showing a 26.9% response rate in treating patients with PD-L1 negative first-line metastatic head and neck squamous cell carcinoma using a combination of efti and KEYTRUDA. The company highlights the potential of efti to enhance immune responses even in patients who traditionally do not respond to existing therapies, with further comprehensive data expected in the first half of 2024. The trial’s success has also led to FDA Fast Track designation for efti in treating this challenging form of cancer.
For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.
